What We Do
Discover
new approaches to developing vaccines and other means of preventing HIV.
Accelerate
translational and clinical research through our laboratories in the U.S., India, and the U.K.
Build Capacity
in-country for researching vaccine candidates while strengthening local public health and scientific expertise.
Partner
with industry and enlist biopharma product development skills to develop innovative products tailored to target populations.
Share
IAVI’s resources with other innovators to help the HIV community as a whole succeed.
Extend
IAVI’s core capabilities to solving disease prevention and treatment challenges.
Latest News from IAVI
Phase I Trial of Native-like HIV Env Trimer
Phase I Trial to Evaluate Safety and Immunogenicity of Engineered Envelope Protein
Need for TB Vaccine Research Support
World TB Day falls on March 24 each year. It marks the day in 1882 when Robert Koch announced that he had identified the cause of TB.
IAVI-Led Study Explores Gene Transfer for HIV Antibody Expression
First-in-human clinical trial results of IAVI A003 study published in The Lancet HIV
IAVI Report: Antibodies & Optimism
Scientists are more optimistic than ever about developing HIV vaccines and antibody-based products.
Donor Spotlight: Netherlands Ministry of Foreign Affairs
IAVI recognizes the Ministry of Foreign Affairs of the Netherlands for its continued support for the development of HIV vaccines and other prevention tools.
The Need for Long-Acting HIV Prevention
Women living in Kenya and South Africa describe the cultural and economic barriers to HIV prevention.
Publications
